Q-omics provides the consensus-scored KRT18P19 profile across patient tissues and cancer cell-line models. KRT18P19 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, KRT18P19 is differentially expressed in 11, with the highest sampling consensus in STAD. Additionally, KRT18P19 RNA expression shows 9,843 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight PAAD, STAD, and ESCA as cancer lineages where KRT18P19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT18P19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT18P19 survival associations across molecular data types. KRT18P19 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT18P19 RNA expression–survival associations across cancer types. High KRT18P19 expression shows unfavorable associations in PAAD, LUAD, MESO and UCEC, but favorable associations in KIRP and LGG. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for KRT18P19 RNA expression.
This table summarizes KRT18P19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for KRT18P19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT18P19 shows higher tumor expression in STAD, KIRP, LUAD, KIRC, COAD and BLCA. The STAD box plot shows higher KRT18P19 RNA expression in tumor versus normal tissue (log2 FC = +0.270, t-test p < 0.001).
This table shows molecular features associated with KRT18P19 in patient tissues and cancer cell lines. In patient samples, KRT18P19 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
